---
document_datetime: 2023-11-09 19:33:57
document_pages: 11
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pregabalin-sandoz-gmbh-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: pregabalin-sandoz-gmbh-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.025334
conversion_datetime: 2025-12-19 05:05:26.052128
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                                                                                                                                                                            | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IA/0032              | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 21/09/2023                                  | n/a                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

Pregabalin Sandoz GmbH Procedural steps taken and scientific information after the authorisation Medicinal product no longer authorised

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0030   | - Stability of FP - Change in storage of the finished product or the product                                                                                                                                                                                         | 13/06/2023   | 15/09/2023    | SmPC, Labelling and PL   | B.II.f.1.d conditions diluted/reconstituted   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|--------------------------|-----------------------------------------------|
| IA/0031   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                          | 05/06/2023   | n/a           |                          |                                               |
| IB/0029   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH         | 05/01/2023   | 20/03/2023    | SmPC and PL longer       |                                               |
| IB/0027   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH product | 18/11/2022   | 20/03/2023 no | SmPC and PL              |                                               |
| IB/0028   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation Medicinal                                                                                                              | 16/11/2022   | n/a           |                          |                                               |
| IA/0026/G | This was an application for a group of variations. B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability -                                                                                                                | 05/09/2022   | n/a           |                          |                                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                 |            |               |                        |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|------------------------|
| IB/0023   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                    | 24/03/2022 | 20/03/2023    | SmPC and PL            |
| IA/0022   | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                                                                                  | 26/01/2022 | n/a           | longer                 |
| IB/0021   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH product                                                                                                                                            | 06/12/2021 | 24/01/2022 no | SmPC, Labelling and PL |
| IB/0019/G | This was an application for a group of variations. B.II.e.1.z - Change in immediate packaging of the finished product - Other variation B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site Medicinal | 03/12/2021 | 24/01/2022    | Annex II and PL        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products                       |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0018   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) 15/06/2021 n/a longer                                                                                                                                                                                                                                                                                 |
| IB/0017   | B.II.a.3.z - Changes in the composition (excipients) of the finished product - Other variation 12/05/2021 n/a no                                                                                                                                                                                                                                                                                                                                                                                       |
| IB/0016/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference 22/01/2021 24/01/2022 Medicinal product |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |                                                                              |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------------------------------------------------------------|
| IA/0015   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 10/07/2020 | n/a authorised                                                               |
| R/0013    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 30/04/2020 | 19/06/2020 SmPC and PL Based the Pregabalin remains renewal validity. longer |
| IB/0014/G | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting Medicinal product | 10/12/2019 | n/a no                                                                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |               |                               |                      |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|-------------------------------|----------------------|
| IB/0012   | B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 30/04/2019    | n/a                           | specification limits |
| IAIN/0011 | B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                            | 23/10/2018    | n/a authorised                |                      |
| IB/0010/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH Medicinal product | 26/01/2018 no | 07/01/2019 SmPC and PL longer |                      |
| IA/0009   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                               | 08/12/2017    | n/a                           |                      |

<div style=\"page-break-after: always\"></div>

| IAIN/0008/G   | This was an application for a group of variations. A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of State - AS   | 27/10/2017   | n/a longer    | a Member   |
|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|------------|
| IB/0006       | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH product                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 06/03/2017   | 05/02/2018 no |            |
| IA/0005/G     | This was an application for a group of variations. B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.e.1.a.1 - Change in immediate packaging of the Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 04/12/2015   | n/a           |            |

<div style=\"page-break-after: always\"></div>

|           | finished product - Qualitative and quantitative composition - Solid pharmaceutical forms B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                  |            |                                             | authorised   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------------------------------------|--------------|
| IB/0003   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                          | 14/10/2015 | 22/09/2016 SmPC                             |              |
| IB/0001/G | This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes product | 02/10/2015 | 22/09/2016 SmPC, Labelling and PL no longer |              |
| IAIN/0004 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site Medicinal                                                                                                                                                                                                                                                                                                                                                       | 30/09/2015 | n/a                                         |              |
| IB/0002/G | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other                                                                                                                                                                                                                                                                                                                   | 24/09/2015 | n/a                                         |              |

<div style=\"page-break-after: always\"></div>

<!-- image -->